Calistoga Pharmaceuticals to Present at Upcoming Investor Conferences
SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that Chief Executive Officer Carol Gallagher, Pharm.D., will present at two investor conferences in November: